NCT01095835 - A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV) | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg

PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.

DRUG

Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg

PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.

DRUG

Lamivudine (LAM)

Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.

Trial Locations (22)

10126

Turin

10149

Turin

20121

Milan

20122

Milan

25125

Brescia

33100

Udine

34100

Trieste

35128

Padua

37134

Verona

40138

Bologna

42100

Reggio Emilia

43100

Parma

56124

Pisa

70013

Castellana Grotte

70124

Bari

71013

San Giovanni Rotondo

80131

Napoli

80135

Napoli

81100

Caserta

90127

Palermo

98124

Messina

09042

Cagliari

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY